{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.96","upperLimit":"8.00","value":"7.00"}]}],"title":"Cycle 0 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.08","upperLimit":"5.98","value":"2.98"}]}],"title":"Cycle 1 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"dispersionType":"Full Range","groups":[{"description":"Participants received an initial priming dose of 600 microgram per kilogram elranatamab subcutaneously on Cycle 0 Day 1 (7 days prior to Cycle 1 Day 1). During treatment cycle, participants were administered 1000 microgram per kilogram elranatamab weekly during each cycle (each cycle was of 3 weeks).","id":"OG000","title":"Elranatamab"}],"paramType":"MEDIAN","populationDescription":"Pharmacokinetic parameter analysis population was defined as all enrolled participants treated who did not have protocol deviations influencing PK assessment and had sufficient information to estimate at least 1 of the PK parameters of interest.","reportingStatus":"POSTED","timeFrame":"Cycle 0: from Cycle 0 Day 1 (pre dose to the next dose of study intervention) [maximum of 9 days]; Cycle 1: from Cycle 1 Day 1 (pre dose to the next dose of study intervention) [maximum of 9 days]","title":"Time to Maximum Concentration (Tmax) of Elranatamab","type":"SECONDARY","unitOfMeasure":"Days"}